Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Core Insights - Abivax (NASDAQ: ABVX) shares experienced a significant increase of 500% on July 23, 2025, due to the company achieving positive data in its clinical trials [2]. Company Analysis - Abivax is involved in the biotechnology sector and has recently reported promising results that have led to a substantial rise in its stock price [2]. - The company is part of a broader analysis service that includes a library of over 600 biotech investing articles and a model portfolio focused on small and mid-cap stocks [2].